Soluble st2 as a marker for risk of mortality in hiv-infected subjects
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Universite Paris Est Creteil Val De Marne
InventorYves Levy
Life of this patent
Estimating the term…
Abstract
The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.
Claims13
A method of predicting the risk of mortality of a HIV-infected subject comprising
- (i) determining the level of sST2 in a biological sample from said subject;
- and
- (ii) comparing said level of ST2 with a control level
- wherein a level of sST2 in the subject sample which is higher than that of the control is indicative of an increased risk of mortality.
A method of prognosis of cardiovascular disease in an HIV-infected subject, said method comprising:
- (i) determining the level of sST2 in a biological sample from said subject;
- and
- (ii) comparing said level of sST2 with a control level;
- wherein a level of sST2 in the subject sample which is higher than that of the control is indicative of a poor prognosis.
A method of monitoring the efficacy of treatment of a cardiovascular disease, said method comprising monitoring sST2 expression during the course of the treatment, wherein a reduction in sST2 level over the course of the treatment is indicative of the efficacy of the treatment.
Dependencies are inferred from the claim text.